Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-3

  Kanakry, Christopher G ^a   Ganguly, Sudipto ^a   Luznik, Leo ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aldehyde dehydrogenase; ALDH; Allogeneic; BMT; Cyclophosphamide; Post transplantation cyclophosphamide; Regulatory T cell; Tolerance; Treg

Indexed keywords

ALDEHYDE DEHYDROGENASE; CYCLOPHOSPHAMIDE;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION ASSAY; CELL TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IN VITRO STUDY; INFLAMMATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 84954545506     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.974393     Document Type: Article

References (10)

1. Berenbaum MC, Brown IN. Prolongation of Homograft survival in mice with single doses of cyclophosphamide. Nature 1963; 200:84; PMID:14074645; http://dx.doi.org/10.1038/200084a0
2. Polak L, Turk JL. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 1974; 249:654-56; PMID:4275846; http://dx.doi.org/10.1038/249654a0
3. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 155:1063-74; PMID:6460831; http://dx.doi.org/10.1084/jem.155.4.1063
4. Brode S, Raine T, Zaccone P, Cooke A. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4CCD25CFoxp3C regulatory T cells. J Immunol 2006; 177:6603-12; PMID:17082572; http://dx.doi.org/10.4049/jimmunol.177.10.6603
5. Tomita Y, Mayumi H, Eto M, Nomoto K. Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance? J Immunol 1990; 144:463-73; PMID:2136891
6. Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLAhaploidentical bone marrow transplantation. Semin Oncol 2012; 39:683-93; PMID:23206845; http://dx.doi.org/10.1053/j.seminoncol.2012.09.005
7. Kanakry CG, Ganguly S, Zahurak M, Bolanos-Meade J, Thoburn C, Perkins B, Fuchs EJ, Jones RJ, Hess AD, Luznik L. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013; 5:211-157; PMID:24225944; http://dx.doi.org/10.1126/scitranslmed.3006960
8. Ganguly S, Ross DB, Panoskaltsis-Mortari A, Kanakry CG, Blazar BR, Levy RB, Luznik L. Donor CD4C Foxp3C regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood 2014; 124:2131-41; PMID:25139358; http://dx.doi.org/10.1182/blood-2013-10-525873
9. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, et al. Functional delineation and differentiation dynamics of human CD4C T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911; PMID:19464196; http://dx.doi.org/10.1016/j.immuni.2009.03.019
10. Busse D, Busch FW, Bohnenstengel F, Eichelbaum M, Fischer P, Opalinska J, Schumacher K, Schweizer E, Kroemer HK. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol 1997; 15:1885-96; PMID:9164199